Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin for benzodiazepine withdrawal
2024-516262-11-00Phase 2Completed
- Sponsor
- St. Olavs University Hospital
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial in benzodiazepine dependence comparing Intranasal oxytocin + benzodiazepine taper with Placebo + benzodiazepine taper (2 arms). Primary endpoint: Benzodiazepine withdrawal symptoms. Started Nov 2024; status: completed.
02
Drugs
oxytocin
03
Conditions
benzodiazepine dependence
Beyond the preview
Go deeper on 2024-516262-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516262-11-00.